ArticleJournal of clinical tuberculosis and other mycobacterial diseases2025
OMNIgene.SPUTUM for transporting sputum in ambient temperature for tuberculosis testing: Bangladesh experience.
Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Performance of OMNIgene.SPUTUM (OM-S) for transporting sputum was evaluated. Methods: This exploratory study was conducted during January-December 2019 at four near and one distant healthcare-facilities of Dhaka. Smear-positive pulmonary TB patients' sputa were collected, divided into 'OM-S untreated' and 'OM-S treated' portions, and transported to testing laboratory, Dhaka, on same-day from near-sites, and through courier from distant-site for smear-microscopy, culture, and Xpert MTB/RIF (Xpert) testing. Subset of 'OM-S treated' sample was tested with Xpert without centrifugation. Test results of all portions were compared in between. Results: Total 444 participants were enrolled (near-sites:198, distant-site: 246). All test results were comparable in both portions for near-sites. For distant-site, smear-microscopy's positivity was reduced by 4.1 % in 'OM-S treated', Xpert showed 100 % concordance in both portions, and culture was higher in 'OM-S treated' than 'OM-S untreated' (92.3 % vs 89.4 %; p = 0.288). Primary contamination rate in 'OM-S treated' was lower than 'OM-S untreated' (2.0 % vs 9.8 %; p < 0.05). For all sites, median (IQR) time-to-culture positivity was 35 (28, 42) days in both portions. Xpert positivity was 99 % concordant in 'OM-S treated' regardless of centrifugation. Conclusions: OM-S is safe for sputum transportation. OM-S mixed sputum can be tested with Xpert and culture. Further studies can validate findings and assess cost-effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.